From the Research
Coxevac vaccine is approved for use in goats in some countries, but its approval status in Canada is unclear, and it is not explicitly mentioned in the provided evidence as being licensed by the Canadian Food Inspection Agency (CFIA) for use in goats within the country. The most recent study 1 from 2023 discusses the use of Coxevac in goats, but it does not provide information on its approval status in Canada. This study focuses on the efficacy of QuilA-adjuvanted Coxevac in goats, highlighting its potential to increase protection against Q fever. However, the regulatory framework for veterinary biologics in Canada may differ from that in other countries, and the absence of explicit mention of Coxevac's approval for goats in Canada suggests that it may not be licensed for this purpose.
- Key points to consider:
- Coxevac is used in some countries for the protection of goats against Q fever.
- The Canadian regulatory framework for veterinary biologics may require Canada-specific efficacy and safety data.
- Goat farmers in Canada typically rely on other preventive measures to control Q fever, such as improved biosecurity practices, regular testing, and quarantine procedures for new animals.
- The most recent study 1 provides evidence on the efficacy of QuilA-adjuvanted Coxevac in goats, but its relevance to the Canadian context is unclear.
- Farmers concerned about Q fever should consult with their veterinarians for the most up-to-date and locally appropriate prevention strategies, as the approval status of Coxevac for goats in Canada is uncertain.